About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eradivir’s EV25 Shows Promising Results in Phase 2a Trial for the Treatment of Influenza

By: via Business Wire

Study Demonstrates EV25’s Safety, Tolerability and Efficacy in Reducing Viral Load and Symptoms

Eradivir Inc., a clinical-stage biotechnology company that targets the power of the immune system to treat disease, today announced the successful completion of its Phase 2a clinical trial for EV25, a therapy for the treatment of influenza. The study demonstrated that EV25 is safe, well-tolerated and significantly reduces viral loads and influenza symptoms, paving the way for a larger Phase 2b trial.

The First-In-Human (FIH), Phase I/2a, placebo-controlled, randomized, double-blind, single-center, single ascending dose (SAD) study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of EV25. The study consisted of two parts: Part 1 involved healthy adult participants, and Part 2 involved healthy adult participants inoculated with an attenuated H3N2 influenza virus. Key findings included:

  • FLU-PRO© Symptom Score Reduction: Treatment with a single 300 mg dose of EV25 demonstrated a significant reduction in total influenza symptom duration and severity as measured by AUC of FLU-PRO total scores, as well as a significant impact on peak total score and body/systemic scores. It also demonstrated a significant decrease in the number of participants with lower respiratory tract infection (35.7% in 300 mg EV25 vs 85.7% in the placebo group, p=0.0065), and a decrease in body/systemic symptom severity.
  • Reduction in Viral Loads: A 300 mg single dose of EV25 significantly decreased the amount of infectious and total attenuated H3N2 influenza virus, with a 98% decrease in median viral load AUC compared to placebo. This large difference occurred early in the disease time course, suggesting EV25 has a rapid impact on the disease.
  • Safety and Tolerability: EV25 was generally safe and well-tolerated with no dose dependent safety trends.
  • Pharmacokinetics: EV25 was quickly absorbed via a liquid intranasal spray. The exposures were linear between doses and well predicted by preclinical models. The PK profiles measured are supportive of a single dose therapy for treating influenza.

“We are thrilled that the Phase 2a results showed that EV25 was well tolerated and demonstrated significant reduction in both viral loads and influenza symptoms,” said Martin Low, Eradivir Chief Executive Officer. “These results are encouraging and support the continued development of EV25 as a potential treatment for influenza. We look forward to advancing EV25 into a larger Phase 2b trial to further evaluate its efficacy.”

Eradivir will conduct EV25’s Phase 2b study in both the United States and Europe in conjunction with the 2026-2027 influenza season. This larger study is expected to include up to 375 participants and further evaluate EV25’s efficacy and dosing.

EV25 was built on Eradivir’s BAiT (Bispecific Antigenic immuno-Therapy) platform that combines the simplicity of small molecules with the efficacy of antibodies. Eradivir’s technology recruits endogenous antibodies to target virus and infected cells to clear the disease. By altering the targeting portion of the molecule, the platform can be leveraged to treat a myriad of diseases.

In addition to EV25, the company is currently evaluating other candidates for the treatments of Respiratory Syncytial Virus (RSV), and Dengue Fever.

ABOUT ERADIVIR

Eradivir Inc. is a privately held, clinical-stage biotechnology company that focuses the power of the immune system to treat viral infections and other diseases. Its proprietary BAiT platform (Bispecific Antigenic immuno-Therapy) combines the simplicity of small molecule therapies with the efficacy of antibody therapies to facilitate rapid and selective diseased cell destruction. Eradivir’s lead antiviral therapeutic EV25 recently completed a successful Phase 2a study and will enter a Phase 2b study in the Fall of 2026. Eradivir’s second drug EV148, a therapy for RSV, is planned for entry into the clinic at the end of 2026. For more information about the company and its latest news, visit www.eradivir.com.

The Phase 2a results showed that EV25 was well tolerated and demonstrated significant reduction in both viral loads and influenza symptoms.

Contacts

More News

View More
AppLovin Drops 14%: Should Investors Worry About SEC Probe?
Via MarketBeat
Topics Regulatory Compliance
Tickers AAPL APP META SPOT
From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift
Via MarketBeat
Topics Artificial Intelligence Energy
Tickers ASX:RUL CAT
Advanced Micro Devices Eyes $300 as AI Demand Surges
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD AMZN GOOGL MSFT NVDA ORCL
Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects
Via MarketBeat
Tickers AMD NVDA QCOM
3 Rare Earth Stocks Powering America’s Critical Minerals Boom
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CRML LAC MP
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.